Cambrex enters finished dosage market with $425m Halo Pharma acquisition

By Flora Southey contact

- Last updated on GMT

(Image: Getty/AmazingDream)
(Image: Getty/AmazingDream)
API maker Cambrex Corporation will add drug development and finished dosage capabilities to its network with the acquisition of CDMO Halo Pharma.

According to the terms, Cambrex will pay $425m (€363m) for the contract development and manufacturing organisation (CDMO), including two manufacturing facilities in New Jersey, US, and Quebec, Canada. The firm’s 450 employees will also transfer to Cambrex.

According to Cambrex, Halo’s core competencies include developing and manufacturing highly complex and difficult to produce formulations, products for paediatric indications and controlled substances.”

“This acquisition opens a completely new segment of the market for Cambrex in finished dose development and manufacturing,” ​said Cambrex CEO Steve Klosk in a statement​.

“Halo’s expertise in oral solids, liquids, creams and ointments fits well with our small molecule API [active pharmaceutical ingredient] business and brings a substantial new customer base and pipeline of small molecules products,” ​he added.

While the move to combine capabilities is in its early stages, Klosk told investors that business development staff from Halo and Cambrex will soon be able to sell all capabilities and services of the combined companies.

For example, Cambrex will be able to offer both API and formulation services, he said during a conference call today: “We believe we will have customers who will value that.”

In addition, Klosk revealed that prior to entering discussions with Cambrex, Halo had been contemplating a move into different dosage forms: “Sterile fill/finish would be an example of this,” ​he added.

“Cambrex has more than enough capital to expand that business,” ​he added.

The deal, which is due to close at the end of Q3 this year, is the latest in a series of investments designed to boost Cambrex’s capabilities. In October 2017​, the firm announced plans to start making high potency APIs at its facility in Milan, Italy, and the following month​, completed the expansion of its small API capacity in Iowa, US.

Earlier this year​, Cambrex said it would invest $5m in a laboratory expansion in Karlskoga, Sweden, and construct a research and development laboratory in Italy.

Related news

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us


View more